This hands-on confirmation provides an essential double-check that goes beyond relying solely on the pharmacy's internal processes
Those who may warrant closer monitoring include: Individuals with pre-existing tachycardia or arrhythmias, such as atrial fibrillation or supraventricular tachycardia Patients with hyperthyroidism, which independently elevates resting heart rate Those taking other medicines that may increase heart rate, including sympathomimetics (such as decongestants and stimulants), serotoninnoradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants, or beta-2 agonists used in asthma management Individuals with a history of heart failure, where even modest increases in heart rate may affect cardiac output and symptom burden though it should be noted that increased cardiovascular risk in this group is based on clinical prudence rather than confirmed harm with GLP-1 receptor agonists Patients receiving higher doses of retatrutide, given the dose-dependent nature of the effect observed in Phase 2 trials Age and baseline cardiovascular health are also relevant considerations
Either way, its not a problem
Patients often describe it as the first time the constant mental negotiation around food gets quiet
Here's how each receptor contributes: GLP-1 is like a "stop eating" signal it reduces appetite and tells the stomach to empty more slowly
While this doesnt directly translate to appetite loss like the GLP-1 agonist effect, it does help improve how the body uses food
